Figure 2: Results of Clinical Trials With CsA in Acute Myocardial Infarction

(A, B) Results of a small phase II clinical trial of cyclosporine A (CsA) in ST-segment elevation myocardial infarction (47): CsA led to a small but statistically significant (p = 0.04) reduction in infarct size measured as plasma creatine kinase (CK) levels over time and as delayed gadolinium enhancement at cardiac magnetic resonance in a subgroup of patients. (C, D) Lack of benefit of CsA in the open-label phase II CYCLE (CYCLosporinE A in Reperfused Acute Myocardial Infarction) trial (51). (E, F) Lack of clinical benefit of CsA in the double-blind CIRCUS (Cyclosporine to ImpRove Clinical oUtcome in ST-elevation myocardial infarction patients) clinical trial (52) in terms of clinical outcomes and surrogate endpoints such as plasma CK levels and resolution of ST-segment elevation. hs-cTnT = high-sensitivity cardiac troponin T; IU = international units; PCI = percutaneous coronary intervention; Q = quartile.



Elsevier user license